The latest offering from ISP is an innovative anti-ageing tetrapeptide, inspired by epigenetic science and designed to boost the expression of clock genes. Recent research has shown that cells can independently tell time via a precise molecular mechanism involving the expression and regulation of circadian genes (Clock, Per1, Bmal1, Tim and Cry). These genes give tempo to cells, orchestrating and regulating over 20% of gene expressions, but they can be desynchronised by external factors such as UV radiation.
The bio-engineered tetrapeptide featured in ISP’s Chronogen improves the expression of the proteins involved in the clock mechanism. It helps preserve skin from UV damage during the day and encourages better DNA repair at night, says ISP.
Chronogen is recommended for use in innovative anti-ageing products based on epigenetic science, as well as day and night time formulations.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
The ingredient making toothpaste work smarter not harder
Read moreAshland’s Ann Druffner and Phil Oths discuss actives retention from toothpaste and mouthwash with a new vegetable oil derivative
Trending Articles
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Ingredients
Can you prioritise both innovation and sustainability at the same time? Learn from a centenarian company
These days, consumers seem to want – and expect – it all. Beyond a wishlist of “nice-to-haves,” they have serious expectations from personal care brands to deliver on an array of criteria and values that were often overlooked before
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.